Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals discovers and develops medicines in cellular metabolism. Lead product is PYRUKYND (mitapivat) for hemolytic anemias. Developing AG-946 for lower-risk myelodysplastic syndrome and hemolytic anemias, and AG-181 for phenylketonuria. Also developing siRNA for polycythemia vera, a rare blood disorder. Company was incorporated in 2007. Headquartered in Cambridge, Massachusetts.
Overview
Strengths
- Current Price to Earnings Ratio (2.93) is lower than the sector mean (91.15).
- Price to book ratio (1.28) is lower than the sector mean (24.44).
Weaknesses
- With a depreciation Potential of -100.00%, based on our fundamental analysis, it suggests the stock may be overvalued.
- Analysts expect revenues to decline in the coming year.
- The company have lower returns than the sector in which it operates. ROIC (0.00%) is significantly lower than the sector mean (6.02%).
- EBITDA Margin (0.00%) appears relatively low.
Key Financial Data
| Indicator | Value |
|---|
| PER | 2.9 |
| EV/EBITDA | 100.0 |
| Price/Free Cash Flow' | 100.0 |
| ROIC | -% |
| Net Debt/EBITDA | 0.0 |